NCAM1 and neoplasm: In 2013, Naomi Pode-Shakked, et al. established for the first time a WT xenograft model simulating an aggressive tumor and showed that by targeting a certain population of cancer cells (enriched in CSC activity i.e.CD56/NCAM), dramatic eradication or attenuation of the tumor can occur in xenograft models (2).